PASG Passage Bio, Inc.
Mergers ·
The amended deal, signed September 2, values Remix at $226.0 million against about $20.0 million for Passage Bio, with $100.0 million of concurrent financing. The final proxy was filed October 9.
Nasdaq confirmed on July 28, 2025 that Passage Bio's shares had closed at $1.00 or more for at least 10 consecutive business days, closing a matter that began in August 2024.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $23.3 million | $40.2 million |
| Net income (loss) | -$45.5 million | -$64.8 million |
| Cash from operations | -$31.5 million | -$48.0 million |
| Cash and equivalents | $46.3 million | $37.6 million |
| Short-term investments | $0 | $39.2 million |
Our latest story on this, dated Oct 9, 2026: "Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5". The story links the filing or release it is based on. Read the story.
Passage Bio, Inc. trades under the ticker PASG on NASDAQ.
Passage Bio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Passage Bio, Inc. is 1787297. Its filings are on SEC EDGAR.
3,217,810 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Passage Bio, Inc. under United States.
Our directory classifies Passage Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Passage Bio, Inc. is US7027122099.
aibio.space lists Passage Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Passage Bio, Inc. reported a net loss of $45.5 million for the fiscal year ended Dec 31, 2025, and used $31.5 million of cash in operations, per its annual report to the SEC.
$23.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$24.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Passage Bio, dated Oct 9, 2026: "Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5". The amended deal, signed September 2, values Remix at $226.0 million against about $20.0 million for Passage Bio, with $100.0 million of concurrent financing. The final proxy was filed October 9. Source.
Our latest listing story, dated Jul 29, 2025: "Passage Bio regains compliance with Nasdaq minimum bid price rule". Nasdaq confirmed on July 28, 2025 that Passage Bio's shares had closed at $1.00 or more for at least 10 consecutive business days, closing a matter that began in August 2024. Source.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,3.02,5.01,5.02,7.01,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,2.06,7.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio